Press Releases
Back to Previous Page
 


News Release

April 4, 2019
Your Contact:
karen.tiano@emdmillipore.com
Phone: +49 6151 72 44461

Merck Recognized with INTERPHEX Exhibitor Award for Best New Product

  • Company wins for first-of-its-kind, single-use tangential flow filtration capsule used in ADC and monoclonal antibody bioprocessing

Darmstadt, Germany, April 4, 2019 — Merck today announced that it has won an INTERPHEX Exhibitor Award for a new innovation in advancing next-generation bioprocessing. Merck’s Pellicon® Capsule with Ultracel® Membrane has been recognized for Best New Product.

“This recognition is for an innovation that enables biomanufacturers to realize the benefits of process intensification throughout the entire bioprocess,” said Andrew Bulpin, head of Process Solutions, Life Science, at Merck. “We will continue to revolutionize drug manufacturing with solutions that set the standard for improvements in process efficiency, simplified plant operations and consistency in manufacturing.”

Merck’s Pellicon® Capsule with Ultracel® Membrane is the first-of-its-kind single-use tangential flow filtration capsule for bioprocessing of antibody-drug conjugates and monoclonal antibodies. The capsule reduces the risk of product cross-contamination, as well as exposure to highly toxic compounds during both processing and disassembly. The self-contained design is ideal for the safe and easy removal of the entire single-use TFF flow path immediately after product recovery, optimizing product changeover efficiency and saving time. The device requires no cleaning validation requirements, thereby reducing its footprint in the manufacturing environment which ultimately leads to increased plant productivity and process flexibility with the added benefit of reduced contamination risks.

Merck works with drug manufacturers to help bring life-enhancing drug therapies to market, faster. Our innovative technologies improve productivity, lower risks, reduce costs and ensure drug safety.

Follow Merck on Twitter @Merckgroup, on Facebook @merckgroup and on LinkedIn.

About Merck

Merck, a leading science and technology company, operates across healthcare, life science and performance materials. Around 56,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – Merck is everywhere. In 2018, Merck KGaA, Darmstadt, Germany generated sales of €14.8 billion in 66 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials.